Portfolio Companies
BioAdvance portfolio companies reflect the breadth and depth of biomedical expertise in Southeastern Pennsylvania. They include medical devices, diagnostics, therapeutics and tool/platform projects. Collectively, the 22 companies that comprise the seed-stage portfolio companies are developing more than 45 products to diagnose or treat diseases such as Alzheimer’s, obesity, diabetes, cancer and infectious diseases.
 |
||
.jpg) |
Acuity used BioAdvance funding to move its RNA interference technology drug for adult macular degeneration –– discovered at the University of Pennsylvania –– into clinical trials. The company raised $16.5 million in 2005 and in 2007 merged with Froptix, renamed Opko Health. | Acuity Pharmaceuticals, Inc. |
|
||
.jpg){kind=small} |
Alteris was focused on the discovery and development of therapeutics and vaccines against novel, proprietary cancer targets. The company’s cancer technologies were purchased by Celldex Therapeutics in 2005. Celldex merged with Avant Immunotherapeutics in 2008. | Alteris Therapeutics, Inc. |
|
||
 |
Avid, out of University of Pennsylvania, is developing novel radiopharmaceuticals for early diagnosis of Alzheimer's disease. The company raised $34.9 million in venture funding to date. | Avid Radiopharmaceuticals, Inc. |
|
||
.jpg){kind=small} |
Cira discovers patterns of biomarkers for diagnostics and drug discovery using its proprietary computational platform. | Cira Discovery Sciences |
|
||
 |
Eagle Vision focuses on imaging agents to enhance magnetic resonance imaging's (MRI) powerful potential for diagnosis and management of heart disease, liver disease and cancer. | Eagle Vision Pharmaceutical Corp. |
|
||
 |
Formae, Inc. was founded by Kevin Mansmann, M.D. (a Fellow of the American Academy of Orthopaedic Surgery and head of Orthopedic Sports and Arthritis Surgery in Paoli, PA). Formae is focused on developing a proprietary pipeline of novel products in arthroscopic joint resurfacing and replacement. | Formae, Inc. |
|
||
 |
Galleon is an early stage company that is developing a new class of medicine for sleep apnea and other conditions related to the body’s regulation of breathing. | Galleon Pharmaceuticals, LLC |
|
||
 |
Gelifex developed novel spine implants for degenerative disc disease. Gelifex was acquired by multi-national device company Synthes, Inc., (Paoli, PA) in 2004. | Gelifex, Inc. (Acquired by Synthes, Inc.) |
|
||
 |
InfraScan is developing the Infrascanner™, which is a hand-held imaging device using near infrared (NIR) technologies for the detection of bleeding in the brain. | InfraScan, Inc. |
|
||
 |
Jenrin is developing a novel approach for the treatment of obesity by developing drugs that act directly to eliminate adipose (fat) tissue. | Jenrin Discovery, Inc. |
|
||
 |
LumenVu, out of the University of Pennsylvania, embedded lights in catheters to guide accurate catheter placement in the body. LumenVu was acquired by SonoSite in 2007. | Lumen Vu |
|
||
 |
Marillion is a clinical-stage pharmaceutical company dedicated to the development and commercialization of novel therapeutics for the treatment of cancersand for supportivecare in oncology. Marillion has raised $2M in additional funding to date. | Marillion Pharmaceuticals, Inc. |
|
||
 |
Melior is a start-up drug development company that is using its theraTRACESM platform to identify new therapeutic uses for development-stage pharmaceutical compounds. Melior raised $5.1 million in 2006 |
Melior Discovery, Inc. |
|
||
 |
Midway is a development-stage biopharmaceutical company focused on creating proprietary drugs for the treatment of bacteria-mediated gastrointestinal (GI) diseases. | Midway Pharmaceuticals, Inc. |
|
||
 |
Niiki Pharma Inc. is developing three novel drug candidates with mechanisms of action that differ from cancer treatments currently on the market and which are designed to preferentially target the cancer cells. Two of these compounds have been tested in patients. | Niiki Pharma Inc. |
|
||
 |
NuPathe is a specialty pharmaceuticals company focusing on the acquisition and development of important and innovative therapeutic products in the area of neuroscience and psychiatry. NuPathe’s product portfolio includes NP101, a novel transdermal patch for the treatment of acute migraine, and NP201, a long acting injectable implant for the treatment of Parkinson’s disease. | NuPathe Inc. |
|
||
 |
Phenotech, out of the University of Pennsylvania, is employing novel molecular technology to develop a new class of renewable, inexpensive, high-quality blood typing reagents. | PhenoTech, Inc. |
|
||
 |
Phoenix S&T develops and markets devices for protein analysis in drug discovery, clinical diagnostics and homeland security. The company’s first product is a nanospray nozzle chip for mass spectrometry analysis. | Phoenix S&T |
|
||
 |
Protez is focused on developing novel antibiotics to combat drug resistance in difficult-to-treat hospital-based infections. Protez raised an additional $21 million, and in 2008 initiated a 20-site, Phase 2 human clinical trial of PZ-601, its lead compound for infectious diseases. |
Protez Pharmaceuticals, Inc. |
|
||
 |
RetinaPharma develops products for vision disorders. RetinaPharma's TonoPach® for glaucoma diagnosis received FDA marketing clearance in 2005. | RetinaPharma Technologies, Inc. |
|
||
 |
SansRosa was focusing on the topical administration of therapeutic agents to treat rosacea and other skin conditions. SansRosa was acquired by CollaGenex, Inc. (Newtown, PA) in 2005. | SansRosa Pharmaceutical Development, Inc. (Acquired by Collagenex, Inc.) |
|
||
.jpg){kind=small} |
SonoMedix is developing a novel nano-acoustic sensor technology for broad application in cardiovascular diagnostics. The first targeted application is blood coagulation self-testing for patients taking Coumadin®. | SonoMedix, Inc. (a Vasculab company) |
|
||
 |
TheraQuest, an analgesic specialist, is developing four novel products for the treatment of moderate-to-severe pain conditions. TheraQuest has raised an additional $3M in funding to date. |
TheraQuest Biosciences , LLC |
|
||
 |
Yaupon has five compounds in its pipeline, including treatments focused on T-cell lymphoma, methamphetamine addiction and ADHD, neuropathic pain, dermatology and CNS. Yaupon has received over $15M in NIH funding and has raised $20M in venture funding to date. |
Yaupon Therapeutics, Inc |
|
||
© Copyright 2008. BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania. All Rights Reserved.